Top Industry Pharma (TI Pharma)
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2006
- Initiating Organization: Top Industry Pharma
- Initiator Type: Nonprofit foundation
- No disease focus
- Location: International
Abstract
Top Institute Pharma (TI Pharma) initiates and manages drug development consortia that involve the pharmaceutical industry, academia, and the Dutch government. The aim of all of the consortia is to conduct precompetitive research while strengthening the Netherlands’ international reputation for drug development. The focus of all their consortia is on five therapeutic areas: autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain.
Mission
TI Pharma was established to initiate and manage drug development consortia to advance the competitiveness of the Netherlands in the pharmaceutical sector, complementing similar Netherlands-based, public-private initiatives to advance diagnostics (Center for Translational Molecular Medicine, CTMM) and devices (BioMedical Materials program, BMM). TI Pharma consortia aim to improve the efficiency of the drug-development process, with a focus on advancing regulatory science. In addition to research, TI Pharma also has objectives to train and educate scientists in the Netherlands on the drug discovery and development processes, as well as on entrepreneurship.
The consortia are focused on addressing therapeutic areas that are listed as priority areas by the World Health Organization. These include autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain. In addition to therapeutic focus, the consortia are also focused on enabling therapeutic target discovery, validation, and animal models; lead selection and in silico modeling; predictive drug disposition and toxicology; biomarkers and biosensors; drug formulation, delivery, and targeting; and production technologies.
Consortium History
2005: Twenty-seven projects selected in first call for proposals
2006: Eighteen projects selected in second call for proposals
Structure & Governance
The TI Pharma strategy is divided into two stages. The first stage, which occurred in 2006, coordinated the Dutch universities and pharmaceutical companies in collaborative research programs (each project is required to have at least three research partners, one of which must represent the industrial or academic community). The second stage started in 2007 with an aim to further increase European involvement via the Seventh Framework Programme, while simultaneously incentivizing participation from U.S.-based pharmaceutical companies.
Participants include all Dutch universities and academic medical centers, more than 30 industrial partners, small-to-medium sized companies, and representatives from the Dutch Medicines Evaluation Board (Netherlands regulatory body for drugs).
Financing
The Dutch government provides €30 million in annual funding, which is matched through financial and in-kind contributions by industry and academia (€15 million, each per year), for four to six years.
Intellectual Property
The TI Pharma consortia follow general principles that govern intellectual property agreements. The principles can be summarized as the following:
Each consortium has one patent coordinator.
Patient Engagement
Several Netherlands patient organizations participate in consortia managed by TI Pharma. These include groups interested in metabolic diseases (VKS: Vereniging Volwassenen, Kinderen en Stofwisselingsziekten), muscle-based diseases (VSN: Vereniging Spierziekten Nederland), and Fabry disease (FSIGN: Fabry Support & Informatie Groep Nederland).
Data Sharing
The level and method of data sharing is dependent on the scientific goals of the consortium.
Impact/Accomplishment
TI Pharma was able to start and manage 96 research consortia within its first six years. Results of the consortia are described in the annual report, which can be found here.
Links/Social Media Feed
Homepage |
|
|
Points of Contact
TI Pharma
PO Box 142
2300 AC Leiden
The Netherlands
phone: 071-332-2030
fax: 071-332-2031
email: info@tipharma.com
Sponsors & Partners
3D-PharmXchange |
Abbott Laboratories |
Abbvie/Shire |
Academic Medical Center Amsterdam |
Actelion |
Aeon Astron Europe |
Agamyxis |
Agendia |
Amgen, Inc. |
Arcarios |
Astellas Pharma Inc. |
AstraZeneca |
Batavia Bioservices |
Bio Detection Systems |
Bio Medical Materials Program |
Bioceros |
Biomade Technology |
BioMarin |
Bionovion |
CardioGenx |
Center for Translational Molecular Medicine |
Centocor |
Centre for Human Drug Research (Netherlands) |
Danone Research |
DC Prime |
Drugs for Neglected Diseases Initiative |
DSM Biomedical |
Dutch Polymer Institute |
Eli Lilly & Co. |
Erasmus University Rotterdam |
Fabry Support & Informatie Groep Nederland |
Feyecon |
Foundation for Innovative New Diagnostics |
Galapagos |
Galapagos/BioFocus |
GE Healthcare |
GlaxoSmithKline |
Glycostem Therapeutics |
Healthcare Insurance Board (Netherlands) |
Holst Centre |
HQ Medical |
Hubrecht Institute |
InteRNA Technologies |
IOTA Pharmaceuticals |
IQ Corporation/IQ Therapeutics |
ISA Pharmaceuticals |
Isconova |
Jan van Es Institute |
Johnson & Johnson |
KNMP/WINap |
Lead Pharma |
Leiden University |
Life Sciences & Health |
Life Sciences & Health cluster organization |
LifeAssay Diagnostics |
Lundbeck A/S |
Maastricht University |
Madam Therapeutics |
Magistro |
Medicines Evaluation Board |
Mercachem |
Merck Sorono/EMD Serono |
Mucosis |
Mymetics |
Nefarma |
Netherlands Cancer Institute |
Netherlands Institute for Health Services Research |
Netherlands Institute for Metal Research |
Netherlands Institute for Neuroscience |
Netherlands Organisation for Applied Scientific Research (TNO) |
Netherlands Vaccine Institute |
NOTOX |
Nycomed |
OctoPlus |
PamGene |
Pansynt |
Pepscan Presto |
Percuros |
Pfizer, Inc. |
Pivot Park Screening Centre |
PRA International |
Prosensa Therapeutics |
PROXY Laboratories |
Radboud University Nijmegen |
Royal Tropical Institute (KIT) |
Sanaria |
Sanofi S.A. |
Sanofi/Genzyme Corp |
Syncom |
Synvolux Therapeutics |
Telematica Instituut |
TropIQ |
UbiQ |
University Medical Center Groningen |
University Medical Center Utrecht |
University of Amsterdam |
University of Bern |
University of Groningen |
Utrecht University |
Vaxinostics |
Vereniging Spierziekten Nederland (VSN) |
Vereniging Volwassenen, Kinderen en Stofwisselingsziekten (VKS) |
Vertex Pharmaceuticals Incorporated |
ViroClinics |
VU University Amsterdam |
Wageningen Centre for Food Sciences |
Wageningen University and Research Center |
Xendo |
ZonMW |